Molecular Oncology Group, Institute of Pathology, Medical Faculty of the RWTH Aachen University, Aachen, Germany.
Oncogene. 2012 Apr 19;31(16):2101-14. doi: 10.1038/onc.2011.403. Epub 2011 Sep 12.
Tumorigenesis and tumor progression are associated with dysfunction of the nuclear transport machinery at the level of import and export receptors (karyopherins). Recent studies have shown that the nuclear import factor karyopherin-α2 (KPNA2) is a novel prognostic marker for poor prognosis in human breast cancer. Based on the well-defined hallmarks of cancer progression, we performed a detailed in vitro characterization of the phenotypic effects caused by KPNA2 overexpression and KPNA2 silencing in benign and malignant human breast cells. KPNA2 overexpression clearly increased proliferation of MCF7 tumor cells and further led to a reduction of cell-matrix adhesion in benign MCF10A cells, whereas cell migration was significantly increased (P<0.0001) in both tumor models. Remarkably, these individual effects of KPNA2 overexpression on proliferation, cell-matrix adhesion and migration resulted in an increased colony spreading of benign MCF10A breast cells and malignant MCF7 tumor cells (P<0.001), which is a hallmark of cancer progression. Conversely, RNA interference-mediated KPNA2 silencing caused a complete inhibition of MCF7 tumor cell proliferation and migration (P<0.0001). In addition, in these experiments apoptosis was increased (P<0.05) and formation of tumor cell colonies was reduced (P<0.01). Thus, KPNA2 overexpression provoked increased aggressiveness of malignant MCF7 breast tumor cells and induced a shift in benign MCF10A breast cells toward a malignant breast cancer phenotype. In conclusion, we demonstrate for the first time in experimental tumor models that forced KPNA2 expression drives malignant features relevant for breast cancer progression, while its silencing is required for the remission of those progressive phenotypes. This study gives clear evidence that KPNA2 acts as a novel oncogenic factor in human breast cancer, in vitro.
肿瘤发生和肿瘤进展与核转运机制在进口和出口受体(核孔蛋白)水平的功能障碍有关。最近的研究表明,核输入因子核孔蛋白-α2(KPNA2)是人类乳腺癌预后不良的一个新的预后标志物。基于癌症进展的明确特征,我们对良性和恶性人乳腺细胞中 KPNA2 过表达和 KPNA2 沉默引起的表型效应进行了详细的体外分析。KPNA2 过表达明显增加了 MCF7 肿瘤细胞的增殖,并且进一步导致良性 MCF10A 细胞中细胞-基质黏附的减少,而细胞迁移在两种肿瘤模型中都显著增加(P<0.0001)。值得注意的是,KPNA2 过表达对增殖、细胞-基质黏附和迁移的这些单独作用导致良性 MCF10A 乳腺细胞和恶性 MCF7 肿瘤细胞的集落扩散增加(P<0.001),这是癌症进展的一个标志。相反,RNA 干扰介导的 KPNA2 沉默导致 MCF7 肿瘤细胞增殖和迁移的完全抑制(P<0.0001)。此外,在这些实验中,细胞凋亡增加(P<0.05),肿瘤细胞集落形成减少(P<0.01)。因此,KPNA2 过表达引起恶性 MCF7 乳腺癌细胞侵袭性增加,并诱导良性 MCF10A 乳腺细胞向恶性乳腺癌表型转变。总之,我们首次在实验性肿瘤模型中证明,强制表达 KPNA2 可驱动与乳腺癌进展相关的恶性特征,而其沉默则是缓解这些进展性表型所必需的。这项研究清楚地表明,KPNA2 在体外作为人类乳腺癌的一种新的致癌因子发挥作用。